Biogen CEO: 'Major bottleneck' still limits Alzheimer's drug
A new Alzheimers drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, continuing a slow debut complicated by...
A new Alzheimers drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, continuing a slow debut complicated by...